From the Chair
From the Chair
Advertisement
Ajay K. Singh, MBBS, FRCP, MBANephrology Times | December 16, 2024
Dr. Ajay Singh discusses the reasons why medical students and residents are not choosing to pursue careers in nephrology.
Read More
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | September 27, 2024
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW. 
Ajay K. Singh, MBBS, FRCP, MBAIgA Nephropathy | August 23, 2024
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Ajay K. Singh, MBBS, FRCP, MBAIgA Nephropathy | August 23, 2024
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
The benefit-risk ratio and considerations about unmet need are worth considering.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
The first part of the dialysis moonshot is to prevent the need for dialysis.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
Ajay K. Singh, MBBS, FRCP, MBAChronic Kidney Disease | February 5, 2024
From the Chair ...
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
From the Chair ...
Ajay K. Singh, MBBS, FRCP, MBAChronic Kidney Disease | February 5, 2024
Managing blood pressure is probably the most important intervention that a nephrologist pursues in slowing kidney ...
Ajay K. Singh, MBBS, FRCP, MBAChronic Kidney Disease | February 5, 2024
Approximately 221 million people worldwide have been diagnosed with infection from SARS-CoV-2, the virus that causes ...
Ajay K. Singh, MBBS, FRCP, MBAChronic Kidney Disease | February 5, 2024
The approval by the US FDA on August 23, 2021, of difelikefalin (marketed as Korsuva™ by Cara Therapeutics) is a major ...
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2021
In a thought-provoking Viewpoint article in JAMA Surgery1, Arthur Matas, MD, makes the case for introducing a regulated ...
Advertisement
Advertisement
Advertisement
Latest News

December 20, 2024